Head-to-head · WeighScore
Maves vs Ozari Health
The verdict
Maves takes it — 71.8/100 to 68.9/100.
Maves grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Maves, operating under parent company Homera Health, is a performance-framed telehealth platform offering compounded semaglutide and tirzepatide for weight loss plus sermorelin for anti-aging, with…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Maves | Ozari Health |
|---|---|---|
| WeighScore | 71.8/100 | 68.9/100 |
| Grade | C | C |
| Scorecard rank | #89 | #136 |
| Semaglutide | $99/mo (starting dose, first-month rate, compounded) | $86/mo (3-mo starter plan, new patients only, compounded) |
| Tirzepatide | Not disclosed | $125/mo (3-mo starter plan, new patients only, compounded) |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #89 · C
Strengths
- LegitScript Certified
- Publishes the FDA compounded-medication disclaimer
- $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
- All 50 states covered, stated explicitly
- Both brand (Maves) and parent (Homera Health) disclosed for accountability
Where it loses points
- 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
- Tirzepatide pricing not stated on the homepage — only listed as an offering
- Named medical director / clinical leadership not disclosed
- Refund and cancellation policy not detailed publicly
- Corporate address and arbitration venue not disclosed
Graded #136 · C
Strengths
- Very low entry pricing — compounded semaglutide from $86/month
- LegitScript certified and operated by a named entity (Ozari LLC)
- Board-certified physicians; meds compounded in 503A and 503B facilities
- Shipping included in the plan price
Where it loses points
- The advertised rates are three-month starter plans for first-time GLP-1 users, billed $257 and $375 up front; month-to-month is $175 and $235
- Cancelling an annual or semi-annual plan early re-prices the installments already shipped at the standard monthly rate and charges the difference
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.